These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 20507732)

  • 1. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
    Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
    Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.
    Huang ZM; Li W; Li S; Gao F; Zhou QM; Wu FM; He N; Pan CC; Xia JC; Wu PH; Zhao M
    J Immunother; 2013 Jun; 36(5):287-93. PubMed ID: 23719239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma].
    Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial].
    Zhao M; Wu PH; Zeng YX; Xia JC; Zhang FJ; Xian LJ; Zhang YP; Zhou K; Fan WJ; Zhang L; Gao F; Zhou QM
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1823-8. PubMed ID: 17054858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in immunological function after treatment with transarterial chemoembolization plus radiofrequency ablation in hepatocellular carcinoma patients.
    Guan HT; Wang J; Yang M; Song L; Tong XQ; Zou YH
    Chin Med J (Engl); 2013; 126(19):3651-5. PubMed ID: 24112158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma.
    Ji Q; Fu Y; Zhu X; Wang L; Ling C
    J BUON; 2021; 26(1):235-242. PubMed ID: 33721457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant cytokine-induced killer cells with minimally invasive therapies augmented therapeutic efficacy of unresectable hepatocellular carcinoma.
    Huang ZM; Lai CX; Zuo MX; An C; Wang XC; Huang JH; Ning E
    J Cancer Res Ther; 2020; 16(7):1603-1610. PubMed ID: 33565506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma.
    Li X; Dai D; Song X; Liu J; Zhu L; Xu W
    Clin Res Hepatol Gastroenterol; 2014 Oct; 38(5):583-91. PubMed ID: 24924902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
    Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
    J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma: a Meta-Analysis.
    Su Y; Yang Y; Ma Y; Zhang Y; Rao W; Yang G; Kou C
    Clin Lab; 2016; 62(4):599-608. PubMed ID: 27215078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
    Cui J; Wang N; Zhao H; Jin H; Wang G; Niu C; Terunuma H; He H; Li W
    Int J Cancer; 2014 Jan; 134(2):342-51. PubMed ID: 23825037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma.
    Wang XP; Xu M; Gao HF; Zhao JF; Xu KC
    World J Gastroenterol; 2013 May; 19(19):2956-62. PubMed ID: 23704829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of CIK in the treatment of TACE combined with RFA for HCC in long-term survival and prognostic analysis].
    Wang JP; Li W; Huang ZL; Wu PH; Li XS; Wei YD; Zhou QM; Pan CC; Xia JC; Zhao M
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3062-6. PubMed ID: 23328379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
    González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
    Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of transcatheter arterial chemoembolization after radiofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma.
    Xu RC; Liu HC; Li JL; Li K; Ou SY; Yu ZY; Kong Y; Ma GA; Shao WS
    Curr Med Res Opin; 2015 Aug; 31(8):1553-60. PubMed ID: 26067770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Fan ZP; Xu DP; Wang FS
    World J Gastroenterol; 2004 Apr; 10(8):1146-51. PubMed ID: 15069715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Cancer Immunol Immunother; 2019 Jan; 68(1):23-32. PubMed ID: 30232520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytokine-induced killer cells transfusion following minimally invasive and interventional therapy for early-stage hepatocellular carcinoma:a long-term study].
    Dong A; Li W; Wu F; Huang Z; Xia J; Wu P
    Zhonghua Yi Xue Za Zhi; 2015 Sep; 95(33):2668-72. PubMed ID: 26711819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study.
    Hao MZ; Lin HL; Chen Q; Ye YB; Chen QZ; Chen MS
    Chin J Cancer; 2010 Feb; 29(2):172-7. PubMed ID: 20109346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.